Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
BIOSTEED GENE TRANSFORMATION TECH. CO., LTD. currently manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These cases are distributed across 3 distinct examiners and 2 distinct art units. BUCCINI, MICHELLE CALLAHAN is the busiest examiner for the portfolio, with 1 pending matter.
This distribution shows that the company's active prosecution is spread across multiple officials while being concentrated in a small number of art units. The company must manage different examiner styles within the biotech sector. Practitioners should monitor the 2 distinct art units to identify any conflicting requirements that might arise during prosecution.
Since the busiest examiner only handles a single case, the firm's strategy is not overly reliant on any one individual's interpretation. This approach allows for a broader range of examiner interactions, which can help the company refine its overall filing strategy as it navigates the complex gene transformation sector. By engaging with multiple examiners, the company can gain diverse perspectives on claim patentability, potentially leading to a more robust portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUCCINI, MICHELLE CALLAHAN | 1 | — | — |
| ABBAS, SYED JARAR | 1 | 0.0% | +0.0% |
| PATTERSON, SARAH COOPER | 1 | 55.3% | +59.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18099664 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | ABBAS, SYED JARAR | — |
| 17629099 | INTERFERON-BASED DISEASE TREATMENT METHOD | PATTERSON, SARAH COOPER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629099 | INTERFERON-BASED DISEASE TREATMENT METHOD | PATTERSON, SARAH COOPER | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18273321 | METHOD AND PHARMACEUTICAL COMBINATION FOR PREVENTING CANCER RECURRENCE | BUCCINI, MICHELLE CALLAHAN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Jul 20, 2023 |
| 18099664 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | ABBAS, SYED JARAR | 1674 | §102§112Other | Non-Final OA | — | Pending | Apr 14, 2023 |
| 17629099 | INTERFERON-BASED DISEASE TREATMENT METHOD | PATTERSON, SARAH COOPER | 1675 | §102§103§112 | Final Rejection | — | Pending | Jan 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial